Literature DB >> 3109739

Modification of natural killer activity of lymphocytes infiltrating human lung cancers.

T M Anderson, Y Ibayashi, E C Holmes, S H Golub.   

Abstract

The purpose of these studies was to compare local and systemic human lymphokine activated killer (LAK) and natural killer (NK) cytotoxic activity and to determine its modulation by biologic agents. Local immunity may be an important component in limiting local tumor growth. Therefore, as a model for studying immune function in the local compartment, we assessed NK activity of lymphocytes present at the site of human tumors and in peripheral blood (PBL). We extracted tumor infiltrating lymphocytes (TIL) and PBL from patients with pulmonary tumors and compared NK activity and response to the biological modifiers gamma interferon (IFN-gamma), indomethacin (INDO), and interleukin 2 (IL-2). We also studied TIL and PBL LAK activity using the NK-resistant M14 target cells and determined the TIL response to IL-2, plus IFN-gamma. Titration of K562 targets in a 51Cr release assay revealed that untreated TIL have low cytotoxicity (4.32%) compared to untreated PBL (34.3%, P = less than 0.001). This low level of TIL NK activity was not affected by IFN-gamma, INDO, or IL-2 at 1 h. However, at 3 days of culture, IL-2 with or without exogenous IFN-gamma significantly increased TIL NK cytotoxicity (20.5%, P = 0.02 without IFN-gamma and 32.52 lytic units (LU), P = less than 0.02 with IFN-gamma). Untreated TIL and PBL both had low cytotoxicity against M14 targets (1.08 LU and 1.26 LU), respectively. After 3 days culture with IL-2 plus IFN-gamma, both TIL and PBL LAK cytotoxicity were increased (14.34 LU and 40.63 LU). We conclude that local NK and LAK activity is intrinsically low. However, this activity can be modulated by biologic agents, thus giving hope for the development of local anti-tumor effectors capable of in vivo tumor control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109739     DOI: 10.1007/bf00199303

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II. Functional investigations of the infiltrating inflammatory cells.

Authors:  T H Tötterman; P Häyry; E Saksela; T Timonen; B Eklund
Journal:  Eur J Immunol       Date:  1978-12       Impact factor: 5.532

2.  Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition.

Authors:  M J Droller; J A Lindgren; H E Claessen; P Perlmann
Journal:  Cell Immunol       Date:  1979-10       Impact factor: 4.868

3.  Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins.

Authors:  G Trinchieri; D Santoli; H Koprowski
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Augmentation of natural killer activity of human peripheral blood lymphocytes by human leukocyte interferon: characterization of the augmented activity.

Authors:  T Amagai; M Kita; J Imanishi; T Kishida
Journal:  Gan       Date:  1983-12

5.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

6.  Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors.

Authors:  P M Moy; E C Holmes; S H Golub
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

7.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity.

Authors:  O Eremin; R R Coombs; J Ashby
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

View more
  4 in total

1.  Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma.

Authors:  T Y Chao; T M Chu
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.

Authors:  I H Ames; G M Gagne; A M Garcia; P A John; G M Scatorchia; R H Tomar; J G McAfee
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer.

Authors:  S B Hosch; A J Meyer; C Schneider; N Stoecklein; K L Prenzel; K Pantel; C E Broelsch; J R Izbicki
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

4.  In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Authors:  J S Economou; A S Belldegrun; J Glaspy; E M Toloza; R Figlin; J Hobbs; N Meldon; R Kaboo; C L Tso; A Miller; R Lau; W McBride; R C Moen
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.